PeptiDream Inc. PPTDF
6.80 USD 0.00 (+0.00%)
At closeNov 10, 2026, 4:00 PM EST
6.80 Day range 6.80
5.88 52-week range 12.85
- YTD
- -45.51%
- 1 year
- -33.59%
News
defenseworld.net PeptiDream (PPTDF) Expected to Announce Quarterly Earnings on Wednesday PeptiDream (OTCMKTS:PPTDF - Get Free Report) is anticipated to post its resultson Wednesday, August 12th. Analysts expect PeptiDream to post earnings of ($0.0196) per share and revenue of $34.8960…
businesswire.com PeptiDream Announces First Dosing of Claudin18.2 Targeting Radiopharmaceutical Candidate 64Cu-PD-29875 in Patients with Gastric Cancer KAWASAKI, Japan--(BUSINESS WIRE)-- #DrugDelivery--The first patient has been dosed with 64Cu-PD-29875 in a first-in-human clinical study in patients with gastric cancer.
businesswire.com PeptiDream, PDRadiopharma and Curium Group Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan KAWASAKI, Japan--(BUSINESS WIRE)-- #Cancer--Completion of patient dosing in the registrational Phase 2 clinical trial of 64Cu-PSMA-I&T —a PET radiopharmaceutical targeting PSMA.
globenewswire.com Curium Group, PeptiDream and PDRadiopharma Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan BOSTON, June 11, 2026 (GLOBE NEWSWIRE) -- Curium Group announced today that together with PeptiDream Inc. and PDRadiopharma Inc., patient dosing has been completed in the registrational Phase 2…
businesswire.com PeptiDream Announces the Initiation of Phase 1 Clinical Trial by Its Collaboration Partner KAWASAKI, Japan--(BUSINESS WIRE)-- #AutoimmuneDisease--PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter “PeptiDream”) today announced…
seekingalpha.com PeptiDream Inc. (PPTDF) Q4 2025 Earnings Call Transcript PeptiDream Inc. (PPTDF) Q4 2025 Earnings Call Transcript
globenewswire.com Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in Japan BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Curium Group today announced that together with PeptiDream Inc. and PDRadiopharma Inc., the first patient has been dosed in the companies' registrational…
businesswire.com PeptiDream Announces Promising Pre-Clinical Results of Proprietary Oral IL-17A and IL-17F Dual Inhibitor with Biologic-Like Efficacy for the Treatment of Psoriasis KAWASAKI, Japan--(BUSINESS WIRE)-- #IL17--PeptiDream is advancing the oral IL-17a/ IL-17F dual inhibitor peptide program into IND-enabling studies, while exploring strategic partnerships.